Publications by authors named "D Gisselsson"
An important aspect of microbiological surveillance is the ability to access live viruses for microneutralization assays, which enables the study of viral characteristics and mechanisms in vitro and production of positive controls for diagnostic methods. During the COVID-19 pandemic, the Public Health Agency of Sweden established a protocol for the rapid collection of clinical samples and subsequent isolation of novel virus variants.
View Article and Find Full Text PDFArticle Synopsis
- Neuroblastoma (NB) is a highly aggressive childhood cancer that often becomes resistant to treatment, making it particularly deadly.
- Researchers studied tumor regions from 12 NB patients and found that, after chemotherapy, the initial densely packed subclones were replaced by diverse "survivor" subclones that had different ancestors.
- The study revealed that tumors progressing during treatment already contained ancestor subclones, indicating a pattern where numerous distinct subclones appear early on and contribute to clonal evolution during chemotherapy.
Article Synopsis
- The ChiCaP study investigates the role of childhood cancer predisposition (ChiCaP) syndromes and how integrating germline whole-genome sequencing (gWGS) with tumor sequencing can improve diagnosis and treatment strategies for children with solid tumors.
- Out of 309 children tested, 11% were diagnosed with ChiCaP syndromes, often missed before, showing significant diagnostic yield especially in certain cancers like retinoblastomas and high-grade astrocytomas.
- The findings underscore the importance of combining systematic phenotyping and genomic diagnostics, as it enables personalized care and tailored treatment recommendations for a substantial number of affected patients.
Article Synopsis
- - Current cancer precision medicine relies heavily on analyzing various genomic changes, with next-generation sequencing (NGS) becoming the primary method for diagnostics in recent years as it offers a comprehensive view of tumors.
- - This shift towards NGS is driven by a need to evaluate more complex biomarkers and genomic variations that influence treatment outcomes, alongside the rapid decrease in sequencing costs and the advent of new targeted therapies.
- - The review emphasizes the historical context of these methods, their clinical relevance in both pediatric and adult cancers, and discusses challenges in implementing them, while also stressing the importance of monitoring treatment response and exploring future advancements in sequencing technology.